The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia

A haplotype relative risk study and association with clozapine response

A. K. Malhotra, D. Goldman, R. W. Buchanan, W. Rooney, A. Clifton, M. H. Kosmidis, Alan Breier, D. Pickar

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Several lines of evidence suggest that the dopamine D3 receptor is involved in the pathophysiology of schizophrenia. The D3 receptor gene (DRD3) contains a polymorphism resulting in a serine-glycine substitution in the N-terminus of the receptor. Shaikh and colleagues have reported a significant association between the DRD3 Ser9 allele and the Ser9/Ser genotype with schizophrenia in 133 Caucasians. In a meta-analysis of previous studies, Ser9 and the Ser9/Ser9 genotype were found to be significantly associated with schizophrenia, investigators could not confirm excess homozygosity at this locus in schizophrenia. These authors also report that, in an unblinded study, the Ser9/Ser9 genotype was more frequent in patients who did not respond to clozapine. These data represent the most comprehensive examination of DRD3 Ser9Gly in schizophrenia to date. We have therefore determined DRD3 Ser9Gly genotypes in 58 patients with schizophrenia and in their parents. Moreover, we have genotyped 68 schizophrenics participating in double-blind clozapine trials. We do not find that Ser9 is preferentially transmitted in schizophrenia, cannot confirm excess DRD3 homozygosity in schizophrenia, and do not replicate the association between DRD3 and clozapine response. These data suggest that allelic variation in DRD3 may not play a role in the pathophysiology of schizophrenia or in clozapine response.

Original languageEnglish (US)
Pages (from-to)72-75
Number of pages4
JournalMolecular Psychiatry
Volume3
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Dopamine D3 Receptors
Clozapine
Haplotypes
Schizophrenia
Genotype
Glycine
Serine
Meta-Analysis
Parents
Alleles
Research Personnel

Keywords

  • Association
  • Clozapine
  • Dopamine 3 receptor
  • Genetics
  • Polymorphism
  • Schizophrenia

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health

Cite this

Malhotra, A. K., Goldman, D., Buchanan, R. W., Rooney, W., Clifton, A., Kosmidis, M. H., ... Pickar, D. (1998). The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response. Molecular Psychiatry, 3(1), 72-75.

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia : A haplotype relative risk study and association with clozapine response. / Malhotra, A. K.; Goldman, D.; Buchanan, R. W.; Rooney, W.; Clifton, A.; Kosmidis, M. H.; Breier, Alan; Pickar, D.

In: Molecular Psychiatry, Vol. 3, No. 1, 1998, p. 72-75.

Research output: Contribution to journalArticle

Malhotra, AK, Goldman, D, Buchanan, RW, Rooney, W, Clifton, A, Kosmidis, MH, Breier, A & Pickar, D 1998, 'The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response', Molecular Psychiatry, vol. 3, no. 1, pp. 72-75.
Malhotra, A. K. ; Goldman, D. ; Buchanan, R. W. ; Rooney, W. ; Clifton, A. ; Kosmidis, M. H. ; Breier, Alan ; Pickar, D. / The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia : A haplotype relative risk study and association with clozapine response. In: Molecular Psychiatry. 1998 ; Vol. 3, No. 1. pp. 72-75.
@article{49a25574f32e4ccfbe8008a02ea56941,
title = "The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response",
abstract = "Several lines of evidence suggest that the dopamine D3 receptor is involved in the pathophysiology of schizophrenia. The D3 receptor gene (DRD3) contains a polymorphism resulting in a serine-glycine substitution in the N-terminus of the receptor. Shaikh and colleagues have reported a significant association between the DRD3 Ser9 allele and the Ser9/Ser genotype with schizophrenia in 133 Caucasians. In a meta-analysis of previous studies, Ser9 and the Ser9/Ser9 genotype were found to be significantly associated with schizophrenia, investigators could not confirm excess homozygosity at this locus in schizophrenia. These authors also report that, in an unblinded study, the Ser9/Ser9 genotype was more frequent in patients who did not respond to clozapine. These data represent the most comprehensive examination of DRD3 Ser9Gly in schizophrenia to date. We have therefore determined DRD3 Ser9Gly genotypes in 58 patients with schizophrenia and in their parents. Moreover, we have genotyped 68 schizophrenics participating in double-blind clozapine trials. We do not find that Ser9 is preferentially transmitted in schizophrenia, cannot confirm excess DRD3 homozygosity in schizophrenia, and do not replicate the association between DRD3 and clozapine response. These data suggest that allelic variation in DRD3 may not play a role in the pathophysiology of schizophrenia or in clozapine response.",
keywords = "Association, Clozapine, Dopamine 3 receptor, Genetics, Polymorphism, Schizophrenia",
author = "Malhotra, {A. K.} and D. Goldman and Buchanan, {R. W.} and W. Rooney and A. Clifton and Kosmidis, {M. H.} and Alan Breier and D. Pickar",
year = "1998",
language = "English (US)",
volume = "3",
pages = "72--75",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia

T2 - A haplotype relative risk study and association with clozapine response

AU - Malhotra, A. K.

AU - Goldman, D.

AU - Buchanan, R. W.

AU - Rooney, W.

AU - Clifton, A.

AU - Kosmidis, M. H.

AU - Breier, Alan

AU - Pickar, D.

PY - 1998

Y1 - 1998

N2 - Several lines of evidence suggest that the dopamine D3 receptor is involved in the pathophysiology of schizophrenia. The D3 receptor gene (DRD3) contains a polymorphism resulting in a serine-glycine substitution in the N-terminus of the receptor. Shaikh and colleagues have reported a significant association between the DRD3 Ser9 allele and the Ser9/Ser genotype with schizophrenia in 133 Caucasians. In a meta-analysis of previous studies, Ser9 and the Ser9/Ser9 genotype were found to be significantly associated with schizophrenia, investigators could not confirm excess homozygosity at this locus in schizophrenia. These authors also report that, in an unblinded study, the Ser9/Ser9 genotype was more frequent in patients who did not respond to clozapine. These data represent the most comprehensive examination of DRD3 Ser9Gly in schizophrenia to date. We have therefore determined DRD3 Ser9Gly genotypes in 58 patients with schizophrenia and in their parents. Moreover, we have genotyped 68 schizophrenics participating in double-blind clozapine trials. We do not find that Ser9 is preferentially transmitted in schizophrenia, cannot confirm excess DRD3 homozygosity in schizophrenia, and do not replicate the association between DRD3 and clozapine response. These data suggest that allelic variation in DRD3 may not play a role in the pathophysiology of schizophrenia or in clozapine response.

AB - Several lines of evidence suggest that the dopamine D3 receptor is involved in the pathophysiology of schizophrenia. The D3 receptor gene (DRD3) contains a polymorphism resulting in a serine-glycine substitution in the N-terminus of the receptor. Shaikh and colleagues have reported a significant association between the DRD3 Ser9 allele and the Ser9/Ser genotype with schizophrenia in 133 Caucasians. In a meta-analysis of previous studies, Ser9 and the Ser9/Ser9 genotype were found to be significantly associated with schizophrenia, investigators could not confirm excess homozygosity at this locus in schizophrenia. These authors also report that, in an unblinded study, the Ser9/Ser9 genotype was more frequent in patients who did not respond to clozapine. These data represent the most comprehensive examination of DRD3 Ser9Gly in schizophrenia to date. We have therefore determined DRD3 Ser9Gly genotypes in 58 patients with schizophrenia and in their parents. Moreover, we have genotyped 68 schizophrenics participating in double-blind clozapine trials. We do not find that Ser9 is preferentially transmitted in schizophrenia, cannot confirm excess DRD3 homozygosity in schizophrenia, and do not replicate the association between DRD3 and clozapine response. These data suggest that allelic variation in DRD3 may not play a role in the pathophysiology of schizophrenia or in clozapine response.

KW - Association

KW - Clozapine

KW - Dopamine 3 receptor

KW - Genetics

KW - Polymorphism

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0031594223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031594223&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 72

EP - 75

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -